CNSP · Insider Trading
CNS Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by CNSP officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Rami Levin | CEO and President | M | −4,750 | — |
| 2026-08-18 | Michal Fisher | Director | Buy | +2,000 | +$10.00K |
| 2026-05-20 | Faith L. Charles | Director | Buy | +7,100 | +$34.00K |
| 2026-03-04 | Steve O'Loughlin | Chief Financial Officer | A | +9,500 deriv. | — |
| 2026-03-04 | Eric Faulkner | Chief Technology Officer | A | +9,500 deriv. | — |
| 2026-01-02 | Rami Levin | CEO and President | A | +19,000 deriv. | — |
| 2025-11-19 | John M Climaco | Chief Executive Officer | A | +9,761 deriv. | — |
| 2025-11-19 | Christopher Downs | Chief Financial Officer | A | +4,881 deriv. | — |
| 2025-11-19 | Faith L. Charles | Director | A | +1,517 deriv. | — |
| 2025-11-19 | Bettina M. Cockroft | Director | A | +1,517 deriv. | — |
| 2025-11-19 | Jerzy Gumulka | Director | A | +1,517 deriv. | — |
| 2025-11-19 | Jeffry R. Keyes | Director | A | +1,517 deriv. | — |
| 2025-11-19 | Amy Mahery | Director | A | +1,517 deriv. | — |
| 2024-08-06 | Cortice Biosciences, Inc. | 10%+ Owner | — | — | — |
| 2024-04-10 | Christopher Downs | Chief Financial Officer | A | +80,000 deriv. | — |
| 2024-04-10 | Jerzy Gumulka | Director | A | +35,000 deriv. | — |
| 2024-04-10 | Carl Anthony Evans | Director | A | +35,000 deriv. | — |
| 2024-04-10 | John M Climaco | Chief Executive Officer | A | +166,000 deriv. | — |
| 2024-04-10 | Bettina M. Cockroft | Director | A | +35,000 deriv. | — |
| 2024-04-10 | Jeffry R. Keyes | Director | A | +35,000 deriv. | — |
| 2024-04-10 | Faith L. Charles | Director | A | +35,000 deriv. | — |
| 2024-04-10 | Amy Mahery | Director | A | +35,000 deriv. | — |
| 2024-02-06 | Amy Mahery | Director | A | +12,420 deriv. | — |
| 2024-02-06 | Christopher Downs | Chief Financial Officer | Buy | +66,666 | +$20.00K |
| 2024-02-06 | John M Climaco | Chief Executive Officer | Buy | +166,666 | +$50.00K |
| 2024-02-06 | Carl Anthony Evans | Director | Buy | +33,333 | +$10.00K |
| 2024-02-06 | Jerzy Gumulka | Director | Buy | +33,333 | +$10.00K |
| 2023-10-12 | Andrzej Andraczke | Director | A | +39,475 deriv. | — |
| 2023-10-12 | Jerzy Gumulka | Director | A | +39,475 deriv. | — |
| 2023-10-12 | Carl Anthony Evans | Director | A | +39,475 deriv. | — |
| 2023-10-12 | Jeffry R. Keyes | Director | A | +39,475 deriv. | — |
| 2023-10-12 | Faith L. Charles | Director | A | +26,315 deriv. | — |
| 2023-10-12 | Bettina M. Cockroft | Director | A | +15,975 deriv. | — |
| 2023-09-25 | Bettina M. Cockroft | Director | A | +16,551 deriv. | — |
| 2023-09-25 | Andrzej Andraczke | Director | A | +68,961 deriv. | — |
| 2023-09-25 | Carl Anthony Evans | Director | A | +68,961 deriv. | — |
| 2023-09-25 | Faith L. Charles | Director | A | +45,974 deriv. | — |
| 2023-09-25 | Jerzy Gumulka | Director | A | +68,961 deriv. | — |
| 2023-09-25 | Jeffry R. Keyes | Director | A | +68,961 deriv. | — |
| 2023-08-23 | Christopher Downs | Chief Financial Officer | Buy | +27,000 | +$34.18K |
| 2023-08-16 | John M Climaco | Chief Executive Officer | Buy | +2,750 | +$4.94K |
| 2023-08-10 | Bettina M. Cockroft | Director | A | +2,099 deriv. | — |
| 2023-08-01 | Waldemar Priebe | 10%+ Owner | Sell | −94,298 | −$133.11K |
| 2023-05-09 | Bettina M. Cockroft | Director | A | +8,300 deriv. | — |
| 2023-05-01 | John M Climaco | Chief Executive Officer | M | +1,250 | — |
| 2023-05-01 | Christopher Downs | Chief Financial Officer | M | +521 | — |
| 2023-04-21 | Jerzy Gumulka | Director | Buy | +2,500 | +$4.25K |
| 2023-04-18 | Christopher Downs | Chief Financial Officer | Buy | +3,100 | +$9.92K |
| 2023-04-17 | Jerzy Gumulka | Director | Buy | +7,173 | +$5.31K |
| 2023-04-14 | John M Climaco | Chief Executive Officer | Buy | +15,000 | +$10.41K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Faith L. Charles | Director | 7,100 | $32.84K |
| Rami Levin | CEO and President | 4,750 | $21.97K |
| Michal Fisher | Director | 2,000 | $9.25K |
| John M Climaco | Chief Executive Officer | 7 | $32 |
| Christopher S Downs | Chief Financial Officer | 3 | $14 |
| Jerzy Gumulka | Director | 1 | $5 |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CNSP quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.